SCHEMBL255294

SCHEMBL255294

CCCS(=O)(=O)Nc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 2/20 0.54
AR P10275 2/20 0.53
HPGD P15428 4/20 0.51
LMNA P02545 3/20 0.51
NR3C2 P08235 1/20 0.51
KDR P35968 2/20 0.51
AURKB Q96GD4 2/20 0.51
AURKA O14965 1/20 0.51
BRD4 O60885 2/20 0.50
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
GAA P10253 2/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 1/20 0.48
HSD17B10 Q99714 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31111910 0.98 KEAP1 (0.52) KEAP1ARHPGDLMNANR3C2
Formic Acid SCHEMBL27731370 0.91 AURKA (0.49) KEAP1ARHPGDLMNANR3C2
SCHEMBL17141394 0.89 AR (0.46) KEAP1ARHPGDLMNANR3C2
SCHEMBL4650966 0.88 AR (0.66) KEAP1ARHPGDLMNANR3C2
SCHEMBL6533144 0.87 CA1 (0.56) KEAP1ARHPGDLMNANR3C2
SCHEMBL251932 0.86 AR (0.60) KEAP1ARHPGDLMNANR3C2
SCHEMBL11210096 0.85 AR (0.58) ARHPGDLMNAKDRAURKB
SCHEMBL14390532 0.85 AR (0.58) ARHPGDLMNAKDRAURKB
SCHEMBL1972989 0.85 HPGD (0.67) KEAP1ARHPGDLMNANR3C2
SCHEMBL12789656 0.83 KEAP1 (0.52) KEAP1ARHPGDLMNANR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2022-03-22 US claimed
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT VALO HEALTH, INC. 2023-11-02 US disclosed
EP-3495782-B1 MAGNETIC ENCODER AND BEARING NSK LTD (JP) 2023-06-14 EP disclosed
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed
EP-3849968-B1 1H-INDAZOLE CARBOXAMIDES AS RECEPTOR-INTERACTING PROTEIN KINASE 1 INHIBITORS (RIPK1) BRISTOL MYERS SQUIBB CO (US) 2022-12-21 EP disclosed
EP-3328843-B1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2022-10-26 EP disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
US-20070142368-A1 Substituted pyrazole compounds MIIKANA THERAPEUTICS, INC. 2007-06-21 US disclosed
WO-2007041358-A2 SUBSTITUTED PYRAZOLE COMPOUNDS MIIKANA THERAPEUTICS, INC. (US) 2007-04-12 WO disclosed
EP-1707923-A1 MAGNETIC ENCODER AND BEARING NSK LTD., (JP) 2006-10-04 EP disclosed
EP-1146037-B1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS NIPPON SODA CO (JP) 2006-06-21 EP disclosed
US-6855787-B2 A multi-layer hose having a multi-layer structure containing an inner layer made of a fluorocopolymer and an outer layer made of polyamide resin ASAHI GLASS COMPANY, LIMITED (JP) 2005-02-15 US disclosed
EP-1470910-A1 Multi-layer hose Asahi Glass Co., Ltd. (JP) 2004-10-27 EP disclosed
US-20040191440-A1 A multi-layer hose having a multi-layer structure containing an inner layer made of a fluorocopolymer and an outer layer made of polyamide resin ASAHI GLASS COMPANY LIMITED (JP) 2004-09-30 US disclosed
US-6410749-B1 REACTING A CARBONYL COMPOUND WITH ORGANOMETALLIC COMPOUND NIPPON SODA CO., LTD. (JP) 2002-06-25 US disclosed
EP-1146037-A1 PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE AMINO ALCOHOLS NIPPON SODA CO., LTD. (JP) 2001-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11279687-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNT, NQO1 KEAP1 576/4885AR 1389/4885HPGD 199/4885
US-20070142368-A1 Substituted pyrazole compounds AURKC, AURKA, AURKB KEAP1 2823/4885AR 2271/4885HPGD 3104/4885
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT KEAP1 278/4885AR 1968/4885HPGD 188/4885
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 KEAP1 258/4885AR 1874/4885HPGD 173/4885
US-20230346753-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 KEAP1 361/4885AR 2931/4885HPGD 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.